7:30 am Check-In & Coffee

8:20 am Chair’s Opening Remarks

Identifying Biomarkers of Aging for Early Detection and Appropriate Clinical Endpoints

8:30 am Advancing Biomarker Detection and Identification for Neurodegenerative Indications

Synopsis

  • Using AI and machine learning to track brain aging
  • Maximising personal data-driven techniques to track biomarkers earlier in life
  • Moving towards preventative therapeutics for neurodegeneration rather than a reactive approach

9:00 am Novel Techniques to Identify Biomarkers in Age-Related Conditions

Synopsis

  • Addressing the challenges in addressing low abundance proteins that can be important markers of aging
  • Accurately following epigenetic and DNA methylation markers
  • Standardizing biomarker techniques across the field

9:30 am Panel Discussion: Leveraging Novel Technology for Identifying Biomarkers of Aging

  • Marco Quarta Co-Founder & CEO Rubedo Life Sciences Inc., Rubedo Life Sciences
  • Priyanka Joshi Co-founder and Chief Scientific Officer, NeuroAge Therapeutics
  • Faizan Zubair Principal Scientist, Takeda
  • Jesse Poganik Instructor in Medicine, Harvard Medical School

Synopsis

  • Understanding how biomarkers can detect subtle changes as molecular and cellular levels before symptoms emerge
  • Discussing the role of biomarkers in precision medicine that address the unique aging process of individuals
  • Outlining the use of epigenetic clocks and advanced imaging techniques to discover novel biomarkers

10:30 am Morning Refreshments & Speed Networking Session

Synopsis

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the age-related therapeutics field and establish meaningful business relationships to pursue for the rest of the conference.

Exploring the Latest Breakthroughs in Novel Technology Targeting the Hallmarks of Aging

11:30 am mRNA-Mediated Epigenetic Reprogramming of Aging: A Safe and New Paradigm in Personalized Regenerative Medicine

Synopsis

  • What is Epigenetic Reprogramming of Aging (ERA) and why it is a paradigm shift
  • Why mRNAs are the solution for a safe epigenetic reprogramming
  • How Turn is enabling the delivery of ERA mRNAs in vivo

12:00 pm Advancements in Senotherapeutics to Develop Novel Therapies

Synopsis

  • Achieving precise targeting of senescent cells to de-risk therapies and prevent unwanted side effects
  • Discussing strategies to overcome senescent cell heterogeneity to improve targeting of senescent cells
  • Developing appropriate biomarkers for the type of senescent cells being targeted
  • Beyond senolytics: other approaches to reduce cellular senescence

12:30 pm Lunch & Networking

1:30 pm Targeting Aging with Senolytic CAR T cells

Synopsis

  • Building a case for CAR T therapies in regenerative medicine and age-related pathologies
  • Developing persistent and lasting effects after single administration

2:00 pm Afternoon Break & Networking

Addressing the Challenges in Clinical Trial Design and Execution for Age-Related Therapeutics

3:00 pm Minimizing Risk in Regenerative Therapies

Synopsis

  • Delivering partial reprogramming to reduce the risk of tumorigenicity
  • Preventing off-target effects and ensuring expression is only seen in the organ of interest
  • Tackling dosage and delivery challenges in regenerative therapies

3:30 pm Selecting the Appropriate Surrogate Endpoint for Aging

  • Joseph Rodgers Co-Founder and Director of Biology, Fountain Therapeutics

Synopsis

  • Utilizing surrogate endpoints to streamline clinical trials and accelerate the de elopement of age-related therapeutics
  • Selecting the correct surrogate endpoint to set up a therapy for being used off-label
  • Ensuring reliability and validity of surrogate endpoints to ensure valid data

4:00 pm Chair’s Closing Remarks and End of Day 1